Active Ulcerative Colitis
9
2
2
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
11.1%
1 terminated out of 9 trials
85.7%
-0.8% vs benchmark
33%
3 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (9)
An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis
A Study of NP-201 Acetate Injection in Healthy Adult Volunteers and in Patients With Mild-To-Moderate Active Ulcerative Colitis
Superdonor FMT in Patients With Ulcerative Colitis
Safety and Efficacy of TJ301 IV in Participants With Active Ulcerative Colitis
Evaluation of Sacral Neuromodulation (SNM) in the Treatment of Active Ulcerative Colitis (PRIMICISTIM)
TID 1000 mg Mesalazine Versus TID 2x500 mg Mesalazine in Active Ulcerative Colitis (UC)
Canadian Active & Maintenance Modified Pentasa Study
A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis
Comparative Efficacy and Safety Study in Patients With Active Ulcerative Colitis